Business Context and Reporting Period
This Form 8-K Current Report was filed by PluriStem Life Systems, Inc. (referred to as Pluri Inc. in metadata) on August 11, 2004. The company is incorporated in Nevada and operates from Haifa, Israel. The report discloses a corporate governance event occurring on August 10, 2004.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of Menachem (Mendi) Ze'evi as a director of the company by the Board of Directors on August 10, 2004. Dr. Ze'evi had previously been appointed Chief Executive Officer on June 10, 2004.
Management Commentary and Background
Management highlights Dr. Ze'evi's extensive background in biotechnology and pharmaceutical management:
- Recent Experience: Served as CEO of Polyheal Ltd. (2000-2003), overseeing business development, R&D, and obtaining CE Mark Certification for a medical device.
- Operational Leadership: Previously held VP roles at InterPharm Laboratories (Serono International) and BioTechnology General (Savient Pharmaceuticals), managing staffs of 25 and 45 respectively in operations and production.
- Education and IP: Holds a Ph.D. in Biochemistry and an M.Sc. in Microbiology, with 13 patents in biotechnology.
The filing does not contain specific guidance, outlook, risks, or contingencies beyond the context of the new director's qualifications.
Key Facts for Investor Verification
- Confirm the effective date of Dr. Ze'evi's directorship (August 10, 2004).
- Verify Dr. Ze'evi's prior role as CEO of the company (appointed June 10, 2004).
- Review the company's current financial status in separate filings (10-K or 10-Q) as this 8-K contains no financial data.
- Assess the strategic impact of adding a director with specific experience in regulatory approvals (CE Mark, FDA) and production scaling.